BioNTech Halts Colorectal Cancer Trial After Safety Board Flags Survival Imbalance
BNTX sits 29% above its 52-week low of $79.52.
Summary
BioNTech terminated its Phase 2 trial of autogene cevumeran in colorectal cancer after the DSMB found a numerical imbalance in overall survival between arms and said continuing was unlikely to change efficacy. The decision, made with partner Genentech, removes a key oncology program from the pipeline. Shares fell 8.2% to $102.22, reflecting investor disappointment in the mRNA monotherapy approach for this tumor type. This follows the 6-K filed earlier today disclosing the termination; the news adds market reaction and DSMB specifics. The setback raises questions about the broader individualized mRNA cancer platform, though the company frames it as scientific insight for future development.
At the time of this announcement, BNTX was trading at $102.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.